keyword
https://read.qxmd.com/read/38703743/off-label-higher-doses-of-serotonin-reuptake-inhibitors-in-the-treatment-of-obsessive-compulsive-disorder-safety-and-tolerability
#1
JOURNAL ARTICLE
Daniel Minkin Levy, Oded Ben Arush, Lior Carmi, Alzbeta Juven Wetzler, Joseph Zohar
OBJECTIVE: To examine the long-term safety and tolerability of off-label high-dose serotonin reuptake inhibitors (OLHD-SRIs) in the treatment of obsessive-compulsive disorder (OCD). METHODS: A retrospective longitudinal study was performed on 105 randomly selected outpatients diagnosed with OCD and were treated with OLHD-SRIs for at least 6 months. Patients received sertraline >200 mg/day, escitalopram >20 mg/day, fluvoxamine >300 mg/day, and fluoxetine >60 mg/day, combined with exposure and response prevention therapy...
April 15, 2024: Comprehensive Psychiatry
https://read.qxmd.com/read/38643950/dysregulation-of-adipogenesis-and-disrupted-lipid-metabolism-by-the-antidepressants-citalopram-and-sertraline
#2
JOURNAL ARTICLE
Deniz Bozdag, Jeroen van Voorthuizen, Nikita Korpel, Sander Lentz, Hande Gurer-Orhan, Jorke H Kamstra
Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used medications for the treatment of major depressive disorder. However, long-term SSRI use has been associated with weight gain and altered lipid profiles. These findings suggest that SSRIs may have negative effects on metabolism. Exposure to certain chemicals called 'obesogens' are known to promote lipid accumulation and obesity by modulating adipogenesis. Here, we investigated whether citalopram (CIT) and sertraline (SER) interfere with the process of adipogenesis, using human mesenchymal stem cells (MSCs) in a 2D and a 3D model...
April 19, 2024: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/38616061/concomitant-treatment-with-safinamide-and-antidepressant-drugs-safety-data-from-real-clinical-practice
#3
JOURNAL ARTICLE
P Pérez-Torre, J L López-Sendón, V Mañanes Barral, I Parees, S Fanjul-Arbós, E Monreal, A Alonso-Canovas, J C Martínez Castrillo
BACKGROUND AND PURPOSE: The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life. METHODS: We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for...
May 2024: Neurología
https://read.qxmd.com/read/38568112/differential-effects-of-sertraline-and-cognitive-behavioural-therapy-on-behavioural-inhibition-in-patients-with-obsessive-compulsive-disorder
#4
JOURNAL ARTICLE
Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg
Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t-tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group...
April 2, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38525466/smoking-blunts-sertraline-response-in-depression-a-prospective-observational-cohort-study
#5
JOURNAL ARTICLE
Prafull Mohan, Kaushik Chatterjee, Sharmila Sinha, R K Saini, A K Sharma, Suraj Waikole
BACKGROUND: Smoking is common in patients of depression and is known to affect response to antidepressants. This study was undertaken to evaluate the effect of smoking on the antidepressant effect of sertraline. METHOD: Patients with depression were divided into smoker and nonsmoker cohorts and followed up for 8 weeks. Serum sertraline levels were estimated using the high-performance liquid chromatography system. Response to treatment was evaluated with the Hamilton Depression Rating Scale (HAM-D)...
2024: Medical Journal, Armed Forces India
https://read.qxmd.com/read/38510645/machine-learning-based-prediction-of-sertraline-concentration-in-patients-with-depression-through-therapeutic-drug-monitoring
#6
JOURNAL ARTICLE
Ran Fu, Xin Hao, Jing Yu, Donghan Wang, Jinyuan Zhang, Ze Yu, Fei Gao, Chunhua Zhou
Background: Sertraline is a commonly employed antidepressant in clinical practice. In order to control the plasma concentration of sertraline within the therapeutic window to achieve the best effect and avoid adverse reactions, a personalized model to predict sertraline concentration is necessary. Aims: This study aimed to establish a personalized medication model for patients with depression receiving sertraline based on machine learning to provide a reference for clinicians to formulate drug regimens. Methods: A total of 415 patients with 496 samples of sertraline concentration from December 2019 to July 2022 at the First Hospital of Hebei Medical University were collected as the dataset...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38399366/a-new-intervention-for-implementation-of-pharmacogenetics-in-psychiatry-a-description-of-the-psy-pgx-clinical-study
#7
JOURNAL ARTICLE
Teuntje A D Pelgrim, Alexandra Philipsen, Allan H Young, Mario Juruena, Ester Jimenez, Eduard Vieta, Marin Jukić, Erik Van der Eycken, Urs Heilbronner, Ramona Moldovan, Martien J H Kas, Raj R Jagesar, Markus M Nöthen, Per Hoffmann, Noam Shomron, Laura L Kilarski, Thérèse van Amelsvoort, Bea Campforts, The Psy-PGx Consortium, Roos van Westrhenen
(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders...
January 23, 2024: Pharmaceuticals
https://read.qxmd.com/read/38390234/synergistic-antidepressant-like-effect-of-xylopic-acid-co-administered-with-selected-antidepressants
#8
JOURNAL ARTICLE
Charles Kwaku Benneh, Wonder Kofi Mensah Abotsi, Robert Peter Biney, Priscilla Kolibea Mante, Mustapha Kobina Abeka, Augustine Tandoh, Eric Woode
BACKGROUND: Xylopic acid (XA), a kaurene diterpene from the dried fruits of Xylopia aethiopica, has anxiolytic- and antidepressant-like activity in mice and zebrafish. We aimed to assess the potential synergistic antidepressant-like effects of XA when combined with selected antidepressants in the mouse forced-swim test. MATERIALS AND METHODS: The antidepressant-like effect of xylopic acid (XA) (10, 30, 100 mgkg-1 ), fluoxetine (Flx) (3, 10, 30 mgkg-1 ), sertraline (Sert) (3, 10, 30 mgkg-1 ), imipramine (Imi) (10, 30, 100 mgkg-1) and ketamine (Ket) (0...
June 2024: IBRO neuroscience reports
https://read.qxmd.com/read/38352761/population-pharmacokinetic-approach-to-guide-personalized-sertraline-treatment-in-chinese-patients
#9
JOURNAL ARTICLE
Zi Zhang, Zhihao Guo, Yaqian Tan, Lu Li, Zhanzhang Wang, Yuguan Wen, Shanqing Huang, Dewei Shang
Object: Sertraline is a first-line SSRI for the treatment of depression and has the same effectiveness along with a superior safety profile compared to other medications. There are few population pharmacokinetic (PPK) studies of sertraline and a lack of studies in the Chinese population. Therefore, we performed a PPK analysis of Chinese patients treated with sertraline to identify factors that can influence drug exposure. In addition, the dosing and discontinuation regimen of sertraline when applied to adolescents was explored...
February 15, 2024: Heliyon
https://read.qxmd.com/read/38330584/sertraline-induced-acute-pancreatitis-a-case-report-and-literature-review
#10
JOURNAL ARTICLE
Ji Yang, Yi Ying, Liying Jin, Fei Ying, Junwei Fang, Xuyong Chen, Mengying Zhu, Xingyi Yang
OBJECTIVE: Acute pancreatitis (AP) is a process of acute inflammation and cell damage of the pancreas. Gallstones and alcohol abuse are the most common cause for AP. Drug-induced pancreatitis (DIP), accounting for less than 3% of the AP, has become increasingly recognized as an additional and vitally important etiology of acute pancreatitis. Sertraline is an antidepressant of the selective serotonin reuptake inhibitor (SSRI)class that has a range of side effects even when used at the recommended dose...
January 31, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38297828/machine-learning-based-prediction-of-escitalopram-and-sertraline-side-effects-with-pharmacokinetic-data-in-children-and-adolescents
#11
JOURNAL ARTICLE
Ethan A Poweleit, Samuel E Vaughn, Zeruesenay Desta, Judith W Dexheimer, Jeffrey R Strawn, Laura B Ramsey
Selective serotonin reuptake inhibitors (SSRI) are the first-line pharmacologic treatment for anxiety and depressive disorders in children and adolescents. Many patients experience side effects that are difficult to predict, are associated with significant morbidity, and can lead to treatment discontinuation. Variation in SSRI pharmacokinetics could explain differences in treatment outcomes, but this is often overlooked as a contributing factor to SSRI tolerability. This study evaluated data from 288 escitalopram-treated and 255 sertraline-treated patients ≤ 18 years old to develop machine learning models to predict side effects using electronic health record data and Bayesian estimated pharmacokinetic parameters...
January 31, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38296462/inhibitory-actions-of-antidepressants-hypnotics-and-anxiolytics-on-recombinant-human-acetylcholinesterase-activity
#12
JOURNAL ARTICLE
Keisuke Obara, Haruka Mori, Suzune Ihara, Kento Yoshioka, Yoshio Tanaka
Alzheimer's disease (AD) is accompanied by behavioral and psychological symptoms of dementia (BPSD), which is often alleviated by treatment with psychotropic drugs, such as antidepressants, hypnotics, and anxiolytics. If these drugs also inhibit acetylcholinesterase (AChE) activity, they may contribute to the suppression of AD progression by increasing brain acetylcholine concentrations. We tested the potential inhibitory effects of 31 antidepressants, 21 hypnotics, and 12 anxiolytics on recombinant human AChE (rhAChE) activity...
2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38212784/sertraline-for-anxiety-in-adults-with-a-diagnosis-of-autism-strata-study-protocol-for-a-pragmatic-multicentre-double-blind-placebo-controlled-randomised-controlled-trial
#13
JOURNAL ARTICLE
Dheeraj Rai, Doug Webb, Amanda Lewis, Leonora Cotton, Jade Eloise Norris, Regi Alexander, David S Baldwin, Traolach Brugha, Madeleine Cochrane, Maria Chiara Del Piccolo, Emma J Glasson, Katherine K Hatch, David Kessler, Peter E Langdon, Helen Leonard, Stephanie J MacNeill, Nicola Mills, Maximiliano Vazquez Morales, Zoe Morgan, Raja Mukherjee, Alba X Realpe, Ailsa Russell, Sergio Starkstein, Jodi Taylor, Nicholas Turner, Joanna Thorn, Jack Welch, Nicola Wiles
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed to manage anxiety in adults with an autism diagnosis. However, their effectiveness and adverse effect profile in the autistic population are not well known. This trial aims to determine the effectiveness and cost-effectiveness of the SSRI sertraline in reducing symptoms of anxiety and improving quality of life in adults with a diagnosis of autism compared with placebo and to quantify any adverse effects...
January 11, 2024: Trials
https://read.qxmd.com/read/38147899/pharmacotherapy-for-the-prevention-of-depression-and-behavioral-side-effects-in-hematopoietic-stem-cell-transplantation-patients
#14
RANDOMIZED CONTROLLED TRIAL
Patricia Mumby, William Adams, Scott Smith, Murali Rao, Patrick Stiff
Depression and decreased quality of life (QoL) develop in approximately 30% of nondepressed hematopoietic stem cell transplantation (HSCT) recipients early after transplantation. To potentially prevent this complication, we conducted a prospective randomized trial to assess whether prophylaxis of nondepressed HSCT patients with the antidepressant sertraline (SER) in addition to supportive psychotherapy starting at admission for transplantation decreases the risk of depression and improves QoL. The primary objective of the study was to evaluate whether there was an added benefit of SER versus placebo along with routine supportive psychotherapy on the development of depression in patients receiving HSCT...
March 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38092320/intranasal-administration-of-sertraline-ensures-sustained-brain-delivery-and-antidepressant-effect-in-a-mouse-model-of-depression
#15
JOURNAL ARTICLE
Soraia Silva, Carla Fonseca, Joana Bicker, Amílcar Falcão, Ana Fortuna
The pursuit of more potent and efficacious antidepressant therapies is of utmost significance. Herein, intranasal (IN) route was investigated for sertraline brain delivery, encompassing a comparative pharmacokinetic study after a single-dose administration to mice by IN, intravenous (IV) (4.87 mg/kg) and oral (10 mg/kg) routes, and an efficacy/toxicity study to explore the therapeutic effect in mice subjected to the unpredictable chronic mild stress (UCMS) protocol. Neurotransmitters and melatonin were quantified in prefrontal cortex and plasma, respectively...
December 11, 2023: European Journal of Pharmaceutics and Biopharmaceutics
https://read.qxmd.com/read/38043099/use-of-sertraline-and-agomelatine-in-hemodialysis-patients-a-case-series-report
#16
JOURNAL ARTICLE
Alicja Kubanek, Mateusz Przybylak, Przemysław Paul, Anna Sylwia Kowalska, Michał Błaszczyk, Aleksandra Macul-Sanewska, Marcin Renke, Przemysław Rutkowski, Leszek Bidzan, Jakub Grabowski
OBJECTIVE: Major depressive disorder (MDD) is one of the most common psychiatric issues in hemodialysis population. However, the research on proper diagnostic tools and its treatment is still insufficient. The study was performed to investigate the safety and effectiveness of sertraline and agomelatine in a group of hemodialysis patients. PATIENTS AND METHODS: 78 adult patients from one dialysis centre in Poland were included into the study. The Beck Depression Inventory II (BDI-II) was used to screen for depressive symptoms and was followed by the clinical interview with the psychiatrist...
December 3, 2023: Acta Biochimica Polonica
https://read.qxmd.com/read/37879445/sertraline-associated-with-gold-nanoparticles-reduce-cellular-toxicity-and-induce-sex-specific-responses-in-behavior-and-neuroinflammation-biomarkers-in-a-mouse-model-of-anxiety
#17
JOURNAL ARTICLE
H M Abelaira, A B de Moura, M M Cardoso, E de Pieri, J S Abel, G P Luiz, E M Sombrio, L A Borghezan, R S Anastácio, L A Cruz, T G de Souza, Correa Meab, I R Lima, C da Costa, A G Dal Bó, Silveira Pcl, R A Machado-de-Ávila
This study aimed to evaluate the effects of sertraline associated with gold nanoparticles (AuNPs) in vitro cell viability and in vivo behavior and inflammatory biomarkers in a mouse model of anxiety. Sertraline associated with AuNPs were synthesized and characterized. For the in vitro study, NIH3T3 and HT-22 cells were treated with different doses of sertraline, AuNPs, and sertraline + AuNPs and their viability was evaluated using the MTT assay. For the in vivo study, pregnant Swiss mice were administered a single dose of lipopolysaccharide (LPS) on the ninth day of gestation...
October 23, 2023: Pharmacology, Biochemistry, and Behavior
https://read.qxmd.com/read/37821319/-premenstrual-dysphoric-disorder-pmdd-drug-and-psychotherapeutique-management-a-literature-review
#18
REVIEW
Hélène Marais-Thomas, Frédéric Chapelle, Véronique de Vaux-Boitouzet, Cyrille Bouvet
INTRODUCTION: Premenstrual Dysphoric Disorder (PMDD) was first recognised in July 2013 in the DSM-5 after a long journey to identify its existence. It was not until 1983 that the US National Institute of Mental Health determined research criteria for the study of PMS. In 1994, the term "premenstrual dysphoric disorder" (PMDD) replaced this term in the 4th edition of the Diagnostic System Manual (DSM). It was listed in the section "Mood Disorder Not Otherwise Specified" and remained under consideration until the DSM-5, in which it appeared in the depressive disorders section...
April 2024: L'Encéphale
https://read.qxmd.com/read/37811114/sertraline-versus-escitalopram-in-south-asians-with-moderate-to-severe-major-depressive-disorder-south-dep-a-double-blind-parallel-randomized-controlled-trial
#19
JOURNAL ARTICLE
Sidra Raza, Saddique Ahmed, Rabia Islam, Muhammad Ahmed, Sandal Ashraf, Hamza Islam, Hifza Kiyani, Muhammad Saqib, Syed A R Shah, Hassan Mumtaz
OBJECTIVE: The study design included the double-blind, parallel, randomized controlled trial. The aim of this randomized controlled trial was to compare the efficacy and safety of sertraline and escitalopram in participants with moderate to severe major depressive disorder (MDD). METHODS: The study was conducted in South Asian participants. A total of 744 participants with moderate to severe MDD were randomly assigned to receive either sertraline or escitalopram for 8 weeks...
October 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/37780150/self-reported-traumatic-brain-injury-in-a-sample-of-impulsive-violent-offenders-neuropsychiatric-correlates-and-possible-dose-effects
#20
JOURNAL ARTICLE
Vasudeva Murthy Challakere Ramaswamy, Tony Butler, Bianca Ton, Kay Wilhelm, Philip B Mitchell, Lee Knight, David Greenberg, Andrew Ellis, Stephen Allnutt, Jocelyn Jones, Val Gebski, Vaughan Carr, Rodney J Scott, Peter William Schofield
BACKGROUND: Traumatic brain injury (TBI) is a major public health problem that may be associated with numerous behavioral problems, including impulsivity, aggression and violence. Rates of self-reported TBI are high within offender populations, but the extent to which TBI is causally implicated in causing illegal behavior is unclear. This study examined the psychological and functional correlates of histories of traumatic brain injury in a sample of impulsive violent offenders. METHODS: Study participants, all men, had been recruited to participate in a randomized controlled trial of sertraline to reduce recidivism...
2023: Frontiers in Psychology
keyword
keyword
108697
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.